These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An open, parallel group study comparing a frusemide/amiloride diuretic and a diuretic containing cyclopenthiazide with sustained release potassium in the treatment of congestive cardiac failure--a multicentre general practice study.
    Author: Allman S, Norris RJ.
    Journal: J Int Med Res; 1990; 18 Suppl 2():17B-23B. PubMed ID: 2193840.
    Abstract:
    A total of 71 patients with cardiac failure requiring diuretic treatment were randomly allocated to receive either 20 mg frusemide/2.5 mg amiloride or 0.25 mg cyclopenthiazide/8.1 mmol sustained release potassium once daily for 12 weeks. Of the 35 patients treated with cyclopenthiazide/potassium, in 47% of patients the daily dose was doubled compared with in only 30% of the 36 patients treated with frusemide/amiloride. Both treatments significantly improved crepitations, oedema, orthopnoea and patient self-assessments of dyspnoea on effort; there were no significant differences between the two treatments. Plasma potassium concentrations were unaffected by either treatment and there were no clinically significant changes in laboratory data. Of the five patients receiving frusemide/amiloride and of the eight receiving cyclopenthiazide/potassium who withdrew from the trial, three and four, respectively, were due to possible drug-related effects. It is concluded that frusemide/amiloride is efficacious and acceptable for the treatment of congestive heart failure.
    [Abstract] [Full Text] [Related] [New Search]